Assembly Biosciences, Inc. (ASMB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 79 | 6 | 0 | 7 | 29 | 72 | 75 | 63 |
| Operating profit | $m | -12 | -9 | ||||||
| Net profit | $m | -62 | -130 | -93 | -61 | -40 | -6 | - | -7 |
| EPS reported | $ | -0.55 | -0.00 | ||||||
| Operating cashflow per share | $ | -3.67 | -2.04 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | -3.67 | -2.05 | ||||||
| Free cash flow | $m | -41 | -39 | ||||||
| Net debt | $m | -248 | -320 | ||||||
| Book value equity | $m | 207 | 306 | ||||||
| Book value per share | $ | 18.44 | 16.21 | ||||||
| Number of shares | m | 11.21 | 18.85 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 42.93 | ||||||
| P/B LTM | x | 1.84 | 1.25 | ||||||
| P/S LTM | x | 5.27 | 5.09 | ||||||
| P/FCF LTM | x | -9.26 | -9.89 | ||||||
| EV/EBITDA LTM | x | -54.31 | 4,786.20 | ||||||
| EV/Sales LTM | x | 4.50 | 9.29 | ||||||
| Earnings Yield LTM | % | -1.61% | +2.33% | ||||||
| FCF Yield | % | -10.79% | -10.11% | ||||||
| Quality | |||||||||
| ROE | % | -2.96% | -0.02% | ||||||
| ROIC | % | -5.79% | -2.86% | ||||||
| Operating margin | % | -16.76% | -11.75% | ||||||
| Gross margin | % | +99.82% | +77.73% | ||||||
| FCF/Sales | % | -56.93% | -51.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +153.52% | +162.43% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -15.66 | -16.41 | ||||||
| Net Debt/EBITDA | x | 9.31 | -440.24 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.20 | -1.05 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Assembly Biosciences, Inc. (ASMB)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free